Answers are grounded in this paper and cite their sources.
Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases. (Funded by Bristol-Myers Squibb and the National Cancer Institute; CheckMate 204 ClinicalTrials.gov number, NCT02320058 .).
No takes yet. Share an insight, caveat, or question.
Tawbi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: